JERSEY CITY, N.J., Feb. 1, 2024 /PRNewswire/ -- The newly published report titled "Global Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing (CDMO) Market- By Application (C.difficle, Crohns disease, IBS, Diabetes) ByType of Services ( Development Services, Manufacturing Services, Others) Trends, Industry Competition Analysis, Covid-19 Analysis, Revenue (US$ Millions) and Forecast Till 2031." features in-depth analysis and an extensive study on the LBP and Microbiome manufacturing industry, exploring its significant factors.
According to the latest market research report by InsightAce Analytic, the Global Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing market size was valued at US$ 141.52 Mn in 2023, and it is expected to reach US$ 993.81 Mn in 2031, record a promising CAGR of 23.19% from 2024 to 2031.
The prominent players in the Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing industry include:
- Quay Pharmaceuticals
- Cerbios-Pharma SA
- List Biological Labs, Inc.
- Arranta Bio (Acquired by Recipharm)
- BacThera
- Biose
- Wacker Biotech
- Other Prominent Players
Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing Market Report Scope:
Report Attribute | Specifications |
Market size value in 2023 | USD 141.52 Mn |
Revenue forecast in 2031 | USD 993.81 Mn |
Growth rate CAGR | CAGR of 23.19% from 2024 to 2031 |
Quantitative units | Representation of revenue in US$ Million, and CAGR from 2024 to 2031 |
Historic Year | 2019 to 2023 |
Forecast Year | 2024-2031 |
Report coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
Segments covered | By Type of Services, Scale of operations, Application |
Regional scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
Request Sample: https://www.insightaceanalytic.com/request-sample/1152
Microbiome research has advanced in recent decades, and it has emerged as a promising area for new medicinal treatments. Microbiome research, in addition to human health, offers a foundation for a broad range of applications. Live Biotherapeutic Products (LBP), or bugs-as-drug, are a new therapeutic modality being developed by several biotech and pharmaceutical businesses across the globe. Live Biotherapeutic Products (LBP) (s), a new type of live-bacteria-based medicines, show promise in treating difficult illnesses. In comparison to the earlier period, the number of new pharmaceuticals licensed for sale increased by 60% between 2010 and 2019, reaching a high of 59 new drugs approved in 2018.
Increasing research and development activities and a growing pipeline of microbiome-targeting therapies anticipated to treat an extensive range of severe diseases are expected to drive market growth over the forecast period. Continued innovation and technological advancements for the new drug development and clinical trial activities for disease treatment are boosting the market growth. Increased R&D budget for drug development and rise in government funding is expected to witness significant growth opportunities during the forecast period. The COVID-19 pandemic is expected to drive the growth of the global Live Biotherapeutic Products (LBP) and microbiome contract manufacturing market.
The COVID-19 outbreak has caused various disruptions in the healthcare industry, as well as a significant influence on clinical trial execution around the world. However, specific requirements for the development of engineered live bacterial therapeutics, lack of infrastructure, and uncertainties related to product approval and regulatory review are some of the other significant factors impacting the market.
Preview for Detailed ToC: https://www.insightaceanalytic.com/report/global-live-biotherapeutic-products-and-microbiome-contract-manufacturing-market-/1152
Key Industry Developments from Leading Players:
- In June 2023, Biose Industrie and SBT Instruments have established a collaboration to integrate rapid viable cell counts into Biose's manufacturing process. SBT's technology will be integrated into Biose's manufacturing process, establishing a new industrial standard for microbe enumeration. The use of quick viable cell counts in both process and release testing intends to minimize the time between clinical trials and market approval for Biose's breakthrough live biotherapeutic companies.
- In Nov 2021, Bacthera and Seres Therapeutics announced a collaboration to manufacture SER-109, Seres' lead product candidate for recurrent Clostridioides difficile infection (CDI). Under the terms of the agreement, Bacteria is establishing a dedicated facility for commercial manufacturing in its new Microbiome Center of Excellence, a manufacturing site dedicated to the production of s located on Lonza's Ibex campus in Visp, Switzerland.
- In May 2021, Bacthera's drug product facility in Basel, Switzerland, and by the Danish Medicines Agency at Bacthera's drug substance facility in Hørsholm, Denmark, both facilities had been granted manufacturing licenses by the respective national health authorities. The permit will allow the Company to fulfill the scope of bringing innovative Live Biotherapeutic Products (LBP) to patients with unmet medical needs
- In Nov 2019, Arranta Bio has received an US$82 million funding round and a strategic partnership with Thermo Fisher Scientific.Through this partnersship with Thermo Fisher, Arranta has access to the company's a wide range of product portfolio and services and provided materials to Thermo Fisher for use in gene therapy production
- In Oct 2019, 4D pharma plc announced research collaboration and option to license agreement with MSD, the tradename of Merck & Co., Inc. to discover and develop Live Biotherapeutics ("s") for vaccines. Through this agreement, 4D's proprietary MicroRx platform will be paired with MSD's expertise in developing and commercializing novel vaccines to discover and develop s as vaccines in up to three undisclosed indications
- In April 2019, Chr. Hansen Holding A/S and Lonza AG equally shared approximately €90m ($101.5m) to establish a CDMO (contract development and manufacturing organization) for biotherapeutic products. The investment was in two phases, bagan with an update to Lonza's existing facilities in Hørsholm, Denmark, for cGMP production of drug substances (anaerobic bacteria).
Global Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing Market Regional Analysis:
North America dominated the global market, contributing for the majority share of the market in 2021. On account of rising R&D spending and the high adoption of new technology, the Region is likely to lead the global market during the forecast period. Intense research and a commercial base for live biotherapeutic and microbiome products and the presence of biopharmaceutical Contract manufacturers are factors contributing to the regional market's growth. Asia Pacific is also projected to expand at the significant growth over the forecast period. Due to key market players' increasing research and development activities, Europe is expected to witness significant growth during the forecast period.
Inquiry Before Buying: https://www.insightaceanalytic.com/enquiry-before-buying/1152
The Global Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing Market Segments
The Global Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing Market Estimates (Value US$ Million) & Forecasts and Trend Analyses, 2024 to 2031 based on Type of Services
- Development Services
- Manufacturing Services
- Others (Regulatory expertise and support, Quality Control and Assurance)
The Global Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing Market Estimates (Value US$ Million) & Forecasts and Trend Analyses, 2024 to 2031 based on Scale of Operation
- Preclinical Scale Operations
- Clinical Scale Operations
- Commercial Scale Operations
The Global Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing Market Estimates (Value US$ Million) & Forecasts and Trend Analyses, 2024 to 2031 based on Application
- C.difficle
- Crohns disease
- IBS
- Diabetes
- Others
The Global Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing Market Estimates (Value US$ Million) & Forecasts and Trend Analyses, 2024 to 2031 based on Region
- Europe
- North America
- Latin America
- Asia Pacific
- Middle East & Africa
North America Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing Market Estimates Revenue (US$ Million) by Country, 2024 to 2031
- U.S.
- Canada
Europe Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing Market Estimates Revenue (US$ Million) by Country, 2024 to 2031
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing Market Estimates Revenue (US$ Million) by Country, 2024 to 2031
- India
- China
- Japan
- South Korea
- Australia & New Zealand
Latin America Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing Market Estimates Revenue (US$ Million) by Country, 2024 to 2031
- Brazil
- Mexico
- Rest of Latin America
The Middle East & Africa Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing Market Estimates Revenue (US$ Million) by Country, 2024 to 2031
- South Africa
- GCC Countries
- Rest of the Middle East & Africa
For Customised Data @ https://www.insightaceanalytic.com/customisation/1152
Other Related Reports Published by InsightAce Analytic:
Live Biotherapeutic Product (LBP) Market Research Report
Personalized and Precision Probiotics Market Research Report
Microbiome in Skincare Market Research Report
Animal Microbiome Market Research Report
Global mRNA Synthesis and Manufacturing Services Market
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact Us:
Priyanka Tilekar
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel: +1 551 226 6109
Asia: +91 79 72967118
Email: info@insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
Logo: https://mma.prnewswire.com/media/1729637/InsightAce_Analytic_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/the-live-biotherapeutic-products-lbp-and-microbiome-contract-manufacturing-cdmo-market-worth--993-81-mn-by-2031---exclusive-report-by-insightace-analytic-302050667.html
